FDA Conflicts of Interest in Peptide Regulation

RFK Jr. claims the FDA's restrictions on certain peptides create conflicts of interest, as the global peptide market could reach $295 billion by 2023. He cites the replacement of advisory panel members with individuals linked to the peptide industry, raising concerns about the integrity of the regulatory process.

AI-generated summary — may contain errors. How it works